The growing interest in potent weight management has resulted in considerable investigation into cutting-edge treatments. Recently , Retatrutide, a twin-action glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist , has demonstrated encouraging results in patient trials, implying potential for substantial weight decrease. As